Innotive Diagnostics (InnotiveDx) today announces the appointment of Andrew Sails, PhD as Director of Research and Development.

Andrew brings over 30 years of experience in microbiology and in vitro diagnostic development, including at Public Health England. Until recently, he was Chief Technical Manager at Cambridge Life Sciences. Before that, he was Director of Microbiology at ODx Innovations, a company that was also developing a UTI diagnostic system before it ceased trading.

Will Wijnberg, Chief Executive Officer of InnotiveDx,said: “We are thrilled that Andrew is joining the team at InnotiveDx. We are building a world class team and Andy is a great addition. He brings considerable experience in UTI diagnostic development and validation, which will be critical as we test our late-stage prototype system over the next 12 months.

Andrew Sails, Director of Research and Development of InnotiveDx,said: “InnotiveDx is an exciting company, backed by impressive science and an excellent team. I am thrilled to have joined at such a pivotal time, as it begins to test and enhance its diagnostic system. The market need for a rapid urinary tract infection (UTI) diagnostic system is huge and I look forward to playing apart in bringing this much-needed system to market and the contribution this will have to improving antimicrobial stewardship.  

About InnotiveDx

InnotiveDx is a privately owned medical device company developing a revolutionary urinary tract infection (UTI) diagnostic system that will diagnose a UTI and provide antimicrobial susceptibility test results within 60 minutes. UTIs are commonly seen in clinical practice and affect hundreds of millions of people per year worldwide, of which more than 71% are women. Currently, most UTI prescriptions are given on an empiric basis leading to significant rates of treatment failure, costing global healthcare systems billions of dollars annually and contributing to antimicrobial resistance.

‍